Compare · DXCM vs GCTK
DXCM vs GCTK
Side-by-side comparison of DexCom Inc. (DXCM) and GlucoTrack Inc. (GCTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GCTK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.85B, about 12012.8x GCTK ($2.8M).
- Over the past year, DXCM is up 20.7% and GCTK is down 95.6% - DXCM leads by 116.3 points.
- GCTK has been more active in the news (13 items in the past 4 weeks vs 10 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for GCTK).
- Company
- DexCom Inc.
- GlucoTrack Inc.
- Price
- $89.69-0.43%
- $3.53-5.11%
- Market cap
- $33.85B
- $2.8M
- 1M return
- +3.19%
- -61.27%
- 1Y return
- +20.72%
- -95.55%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 10
- 13
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
GlucoTrack Inc.
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Latest DXCM
- Dexcom Announces Upcoming Conference Presentation
- EVP Chief People & Culture Off Stern Sadie sold $226,669 worth of shares (2,565 units at $88.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 126,043 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
Latest GCTK
- Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business
- GlucoTrack Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 425 filed by GlucoTrack Inc.
- Amendment: GlucoTrack Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets
- GlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Glucotrack, Inc. Announces Reverse Stock Split
- Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100
- SEC Form DEFA14A filed by GlucoTrack Inc.
- Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia
- GlucoTrack Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders